| Primary |
| Nuclear Magnetic Resonance Imaging |
29.8% |
| Angiogram |
12.8% |
| Nuclear Magnetic Resonance Imaging Brain |
12.8% |
| Hypertension |
7.0% |
| Pain |
4.3% |
| Prophylaxis Against Transplant Rejection |
4.2% |
| Diabetes Mellitus |
3.7% |
| Scan |
2.7% |
| Cardiac Disorder |
2.4% |
| Anticoagulant Therapy |
2.4% |
| Anaemia |
2.3% |
| Blood Pressure |
2.3% |
| Dialysis |
2.2% |
| Drug Use For Unknown Indication |
2.1% |
| Blood Cholesterol Increased |
2.1% |
| Gastrooesophageal Reflux Disease |
1.7% |
| Sleep Disorder |
1.4% |
| Supplementation Therapy |
1.3% |
| Mineral Supplementation |
1.3% |
| Nuclear Magnetic Resonance Imaging Abdominal |
1.2% |
|
| Nephrogenic Systemic Fibrosis |
43.6% |
| Off Label Use |
12.8% |
| Vomiting |
9.3% |
| Weight Decreased |
4.0% |
| Vertigo |
3.0% |
| Vision Blurred |
2.8% |
| Oedema Peripheral |
2.5% |
| Throat Tightness |
2.0% |
| Urticaria |
2.0% |
| Wound |
2.0% |
| Injection Site Extravasation |
1.8% |
| Nephrogenic Fibrosing Dermopathy |
1.8% |
| Splenomegaly |
1.8% |
| Tremor |
1.8% |
| Urinary Tract Infection |
1.8% |
| Wound Infection Staphylococcal |
1.8% |
| Ventricular Tachycardia |
1.5% |
| Wheezing |
1.5% |
| Nausea |
1.3% |
| Transplant Failure |
1.3% |
|
| Secondary |
| Nuclear Magnetic Resonance Imaging |
52.5% |
| Angiogram |
13.6% |
| Nuclear Magnetic Resonance Imaging Brain |
6.3% |
| Imaging Procedure |
3.9% |
| Drug Use For Unknown Indication |
3.6% |
| Product Used For Unknown Indication |
2.9% |
| Hypertension |
2.8% |
| Nuclear Magnetic Resonance Imaging Abdominal |
2.1% |
| Pain |
2.0% |
| Diabetes Mellitus |
1.5% |
| Diagnostic Procedure |
1.2% |
| Dialysis |
1.2% |
| Fistulogram |
1.2% |
| Venogram |
1.0% |
| Prophylaxis Against Transplant Rejection |
1.0% |
| Anaemia |
0.9% |
| Cardiac Disorder |
0.6% |
| Arteriogram |
0.6% |
| Blood Cholesterol Increased |
0.5% |
| Mineral Supplementation |
0.5% |
|
| Pain |
20.2% |
| Skin Tightness |
14.1% |
| Nephrogenic Systemic Fibrosis |
13.5% |
| Skin Fibrosis |
11.4% |
| Scar |
9.6% |
| Skin Induration |
4.4% |
| Off Label Use |
3.5% |
| Skin Hypertrophy |
2.7% |
| Splenomegaly |
2.6% |
| Skin Ulcer |
2.6% |
| Anxiety |
2.1% |
| Swelling |
1.9% |
| Injury |
1.7% |
| Skin Lesion |
1.6% |
| Vomiting |
1.5% |
| Mobility Decreased |
1.3% |
| Skin Plaque |
1.3% |
| Xerosis |
1.3% |
| Joint Range Of Motion Decreased |
1.3% |
| Oedema Peripheral |
1.3% |
|
| Concomitant |
| Drug Use For Unknown Indication |
22.2% |
| Amnesia |
11.1% |
| Deafness Unilateral |
11.1% |
| Eustachian Tube Dysfunction |
11.1% |
| Mastoiditis |
11.1% |
| Nuclear Magnetic Resonance Imaging |
11.1% |
| Nuclear Magnetic Resonance Imaging Brain |
11.1% |
| Otitis Media |
11.1% |
|
| Nephrogenic Systemic Fibrosis |
62.5% |
| Grand Mal Convulsion |
37.5% |
|
